MaggieSantos
☆    

Portugal,
2016-10-28 20:16
(2707 d 20:00 ago)

Posting: # 16755
Views: 3,329
 

 Ambroxol Sustained Release 75 mg [Design Issues]

Dear colleagues,

I have been asked to perform a bioequivalence study on ambroxol, sustained release formulations containing 75 mg. according to guideline a single dose fast study as well as a single dose fed may be applicable. The multiple dose study is also required due to accumulation, according to ambroxol half-life between 7 and 12 hours.

I would like to have inputs from experienced researchers in order to aware of any concerns related to this substance.

Kind Regards
DavidManteigas
★    

Portugal,
2016-11-02 11:51
(2703 d 03:25 ago)

@ MaggieSantos
Posting: # 16764
Views: 2,619
 

 Ambroxol Sustained Release 75 mg

Hi Maggie,

Which guideline are you refering? EMA or FDA? Didn't find any product-specific guideline on ambroxol bioequivalence...

If you're refering to a more general guidance, FDA guideline for BE studies with pharmacokinetic endpoints states de following (section IV, D, 3):

For modified release products, we recommend the following studies: (1) a single-dose, fasting study comparing the highest strength of the test with the RLD, and (2) a single-dose fed BE study comparing the highest strength of the test with the RLD product. Because single-dose studies are considered more sensitive in addressing the primary question of BE (e.g., release of the drug substance from the drug product into the systemic circulation), multiple-dose studies are generally not recommended
UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,638 registered users;
81 visitors (0 registered, 81 guests [including 9 identified bots]).
Forum time: 15:17 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5